New research from the BPLTTC study supports the notion that people with normal blood pressure can prevent heart attacks and strokes by taking prophylactic blood pressure-lowering medication. These data will add fuel to the discussion of current and future blood pressure thresholds.
Prof. Kazem Rahimi (University of Oxford, UK) presented a meta-analysis of data from 348,854 participants from 48 clinical trials [1]. Participants were divided according to whether they had a prior diagnosis of cardiovascular disease, then further stratified according to 1 of 7 blood pressure groups ranging from systolic blood pressures of <120 mmHg up to ≥170 mmHg at study entry.
With an average follow-up of 4 years, the investigators noted a progressive reduction in relative risk of major cardiovascular events by roughly 10% for each 5 mmHg reduction in systolic blood pressure, including for the lowest systolic blood pressure category of <120 mmHg, in both primary and secondary prevention settings (see Figure). Risk for stroke, ischaemic heart disease, heart failure, and death from cardiovascular disease was reduced by 13%, 7%, 14%, and 5%, respectively. The benefits were similar along the entire range of systolic blood pressures.
Figure: Effects on major cardiovascular events for each 5 mmHg SBP reduction, by CVD status at baseline [1]
CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; SBP, systolic blood pressure.
In his interpretation of these results, Prof. Rahimi cautioned that “the fact that the relative effects are similar for everyone does not mean that everyone should be treated.” He went on to suggest the decision to prescribe blood pressure-lowering medication should not be based simply on a prior diagnosis of cardiovascular disease or an individual’s current blood pressure, but rather used as “risk-modifying treatments for prevention of incident or recurrent cardiovascular events, regardless of blood pressure values at baseline.”
-
- Rahimi K, et al. BPLTTC – Blood pressure lowering for prevention of cardiovascular events across different levels of blood pressure. Hot Line 3 session, ESC 2020 E-Congress, 31 Aug.
Posted on
« COVID-19: Continuing versus suspending ACE inhibitors and ARBs Next Article
Similar outcomes sPESI and HESTIA for pulmonary embolism triage »
Table of Contents: ESC 2020
Featured articles
2020 ESC Clinical Practice Guidelines
2020 Atrial Fibrillation Guidelines
2020 Non-ST-Segment Elevation Acute Coronary Syndromes Guidelines
2020 Sports Cardiology and Exercise in Cardiovascular Patients Guidelines
2020 Adult Congenital Heart Disease Guidelines
Hot Line Presentations
SGLT2 inhibitor improves cardiovascular outcomes in heart failure patients
First-in-class cardiac myosin inhibitor effective in obstructive hypertrophic cardiomyopathy
Reduced cardiovascular outcomes with early rhythm control
Trimetazidine after successful PCI not associated with fewer cardiac events
POPular TAVI: Aspirin-only antiplatelet strategy?
Reduced NT-proBNP in HFpEF with sacubitril/valsartan
DAPA-CKD: Dapagliflozin improves CKD survival ± diabetes
Low-dose colchicine reduces CV death and ischaemic events in coronary disease
Similar outcomes sPESI and HESTIA for pulmonary embolism triage
Antihypertensives also reduce CV risk in people with normal blood pressure
COVID-19: Continuing versus suspending ACE inhibitors and ARBs
Drug initiation strategy not associated with increased use of oral anticoagulants
Restrictive blood transfusion non-inferior and cost-effective strategy
Late-Breaking Science
Increased mortality with colchicine in patients with ACS
Rivaroxaban protects limbs and ischaemic events in CAD-PAD patients
Antisense APOC3 oligonucleotide lowers triglyceride and atherogenic lipoproteins
Antisense ANGPTL3 lowers triglycerides
Reduced progression of coronary atherosclerosis with icosapent ethyl
Digoxin improves symptoms in stable patients with permanent AF
SGLT2 inhibitor ertugliflozin shows similar mortality but fewer HF hospitalisations
COVID and Cardiovascular Disease
Risk factors for thromboembolism and bleeding in COVID-19: lessons from Wuhan
The Yale COVID-19 Cardiovascular Registry
COVID-19 treatments and the importance of randomised trials
Related Articles

Reduced NT-proBNP in HFpEF with sacubitril/valsartan
2020 Non-ST-Segment Elevation Acute Coronary Syndromes Guidelines
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy